Real-World Effectiveness of Risankizumab in Patients With Psoriatic Arthritis: 6-Month Interim Results From the Observational PErsistence With RISankizumab (PERIS) Study (ACR Convergence 2026) - Sep 8, 2026 - Abstract #1326; Pres time: Nov 9, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; P | "In this observational study, patients treated with RZB up to 6 months showed improvements in overall disease activity, as well as in joint, enthesitis, dactylitis, and skin domains, supporting the real-world effectiveness of RZB in PsA, consistent with existing clinical trial data."
Clinical • Real-world • Real-world effectiveness • Real-world evidence • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL23A
|
|
Carlo Selmi1; Georgios Vosvotekas2; Nikolaos Kougkas3; Philipe Goupille4; Anastas Batalov5; Jan Brandt-Juergens6; Thomas Iyile7; Xiao Li8; Meng Zhang7; Ralph Lippe7; Tae Jin Park7; Fabian Proft9
|